Ipamorelin vs Sermorelin

Side-by-side comparison of Ipamorelin, Sermorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone Sermorelin Sermorelin Acetate (GHRH 1-29) Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)GHRH Analogue
Amino acids 529
Molecular weight 711.9 Da3,357.9 Da
Half-life ~2 hours~10–20 min
Route(s) Subcutaneous, IntramuscularSubcutaneous, IV (diagnostic only)
Mechanism & Research
Primary mechanism Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough … Sermorelin binds GHRH receptors in the anterior pituitary with similar affinity to native GHRH and stimulates GH synthesis and secretion. Its mechanism is essentially identical to endogenous GHRH — it is distinguished pr…
Research status Research Compound Research Compound
Evidence summary Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in… Sermorelin has more human clinical data than any other GHRH analogue due to its period of FDA approval. Adult studies have examined it for age-related GH decline, body composition, and sleep quality.
Protocol & Dosing
Typical dose 100–300 mcg per injection200–500 mcg
Frequency 2–3x daily (or 1x at bedtime)Once daily at bedtime
Duration 8–12 weeks on, 4 weeks off3–6 months
Timing Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulseBedtime (maximises nocturnal GH pulse)
Safety
Common side effects
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
  • Injection site pain/redness
  • Flushing
  • Headache
  • Dizziness (rare)
Contraindications
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
  • Active malignancy
  • Hypothyroidism (treat first)
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides CJC-1295, GHRP-2, Sermorelin, Tesamorelin CJC-1295, Ipamorelin, Tesamorelin
Full profile Read full Ipamorelin profile → Read full Sermorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.